AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05507112 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long-course radiation therapy
Description: 45-50 Gy/day, 5 days a week for a total of 5 weeks.
Study NCT05507112 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long-course radiation therapy
Description: 45-50 Gy/day, 5 days a week for a total of 5 weeks.
Study NCT06175949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7085 Tablets
Description: HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
Study NCT06175949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS-7085 simulant
Description: PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Study NCT05072808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: View PACCI-ED and referral recommendations
Description: Results of parent completed PACCI-ED and referral recommendations
Study NCT00900588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
Study NCT00900588 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
Study NCT04705662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lactulose breath test
Description: Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
Study NCT04705662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample
Description: Participants will provide a stool sample pre and post iron supplementation
Study NCT04705662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Daily Diary
Description: Monitoring stool form, consistency and frequency on a daily basis
Study NCT04705662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire
Description: Participants will complete the questionnaire pre and post iron supplementation
Study NCT04705662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Sulphate
Description: Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
Study NCT06344897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
Study NCT05861817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser theapy
Description: participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
Study NCT05861817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser theapy
Description: participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
Study NCT05844462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Oral Tadalafil
Study NCT05844462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT05502172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
Study NCT06293820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.
Study NCT06293820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study NCT05550519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV will continue throughout screening and will be stopped at baseline.
Study NCT05550519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Description: TDF will continue throughout screening and will be stopped at baseline.
Study NCT05550519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: TAF will continue throughout screening and will be stopped at baseline.
Study NCT06153550 — intervention group
Intervention type: OTHER
Intervention: preparation in Respiratory Physiotherapy
Description: preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery.
Study NCT05262179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0101
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2
Study NCT05262179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2
Study NCT00013156 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Effectiveness of Lung Reduction Therapy
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given by vein (IV)
Study NCT05110612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
Study NCT05110612 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Episodic Thinking
Description: Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
Study NCT05731349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2018 Surviving Sepsis Campaign Hour-1 Bundle
Description: 1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg
Study NCT05212818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF0023
Description: Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
Study NCT05179200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasma donation
Study NCT05179200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Description: Plasma donation
Study NCT05179200 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Whole blood donation
Description: Blood donation
Study NCT06030362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Dietary Supplement taken once daily for 3 months (90 days).
Study NCT06030362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement taken once daily for 3 months (90days).
Study NCT04989933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided erector spinae plane block
Description: Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
Study NCT01173250 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: adding diverting ileostomy
Study NCT01173250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: omitting diverting ileostomy
Study NCT05395585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual placental separation
Description: Manual separation of the placenta from uterus
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given by vein (IV)
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL
Description: Given by vein (IV)
Study NCT04148456 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Covered Endovacular Reconstruction of Aortic Bifurcation
Description: * The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~* After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~* A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~* The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation.
Study NCT06425614 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autotransfusion
Description: ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.
Study NCT05311878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based perceptual training
Description: Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
Study NCT05311878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Behavior based perceptual training
Description: Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein (IV)
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)
Study NCT06425614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Description: ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.
Study NCT05708885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction
Description: To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
Study NCT05708885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device
Description: Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
Study NCT06576037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given by mouth
Study NCT05203445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg orally BID
Study NCT05203445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg intravenously q6weeks
Study NCT04968912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion will be administered intravenously.
Study NCT04968912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
Study NCT04968912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Treatment
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Study NCT04968912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
Study NCT06022107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LDART
Description: LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
Study NCT05693961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
Study NCT06436859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress ball group
Description: According to randomization, pregnant women in the intervention group will receive stress ball therapy during labor.
Study NCT06341985 — intervention group
Intervention type: RADIATION
Intervention: Exclusive radiotherapy
Description: Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
Study NCT06277167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon alfa 1b inhalation solution
Description: Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
Study NCT06277167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human interferon alfa 1b inhalation solution placebo
Description: Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
Study NCT06277167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human interferon alfa 1b inhalation solution
Description: Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
Study NCT06277167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human interferon alfa 1b inhalation solution placebo
Description: Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
Study NCT05608863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle - group sessions
Description: The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
Study NCT05608863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle - individual coaching
Description: The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
Study NCT03235232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BREMEN eye drops
Description: 1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Study NCT03235232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combigan®
Description: 1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Study NCT05620121 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for Incisional hernias
Description: Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
Study NCT06551844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg
Description: This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.~In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed.
Study NCT06551844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS513 (a monoclonal antibody)
Description: VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.
Study NCT05627804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise
Description: The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia